Background: Pharmaceutical firms heavily promote their products and may have changed marketing strategies in response to reductions in new product approvals, restrictions on some forms of promotion, and the expanding role of biologic therapies.
Introduction
In the United States, pharmaceuticals are heavily promoted to providers and patients. The pharmaceutical industry spent nearly $30 billion dollars in 2005 on marketing and promotion, of which 84% went toward physician detailing and free samples, with less devoted to professional advertising and direct-to-consumer advertising (DTCA) [1, 2] . Spending varied considerably by product, although both detailing and DTCA tended to favor drugs with broader clinical indications for use [3] . Pharmaceutical promotion can influence demand for prescription drugs [4] , increase physician visits for conditions treated by heavily advertised drugs [5] and affect physician prescribing [6] .
Little is known about how pharmaceutical companies have altered promotional spending in response to major health care changes. First, during the past decade there has been a slowdown in new drug introductions. During the second half of the 1990s, the FDA approved a large number of small molecule therapies for common conditions, including many drugs that were the first of their kind. These ''blockbuster'' drugs were heavily marketed, resulting in a 162% increase in total promotional spending between 1996 and 2005 [1] . In recent years, however, blockbuster drugs have faced increasing competition from generics, as well as branded rivals, with the generic share of total prescriptions increasing markedly from 63% in 2006 to nearly 80% in 2010 [7] . Fewer new drugs have been approved annually in recent years [8] , and a greater proportion of those introduced have been for orphan conditions [9] . Second, drugs manufactured using biologic processes, or ''biologics'', represent an increasing proportion of newly approved products and drugs sales [10, 11] . Biologics comprised over 40% of products in late stage research and development in 2009, suggesting that they may account for an increasing proportion of new products launched in the near future [10] . Since these products are often used by a smaller number of patients, administered parenterally by providers, and sold at much higher prices, the promotional strategies may differ substantially compared to small molecule therapies. Finally, in response to mounting empirical evidence as well as legal challenges, media scrutiny [12] , and the recommendations of professional societies [13] , numerous medical centers have limited pharmaceutical sales representatives access to physicians [14] [15] [16] . Furthermore, certain states now require disclosure of gifts from pharmaceutical companies to providers [17] . While there is some evidence of decreases in industry interaction with office-based physicians [18, 19] , it is unclear how industry practices have changed in response to these provisions.
We examined trends in promotion to consumers and providers over the last decade. We hypothesized decreases in absolute spending on promotion to providers and DTCA, with an increasing share of detailing devoted to specialists given the expanding role of biologics. In addition to trends for the pharmaceutical industry overall, we compared the promotional strategies of top-selling small molecule and biologic therapies. Finally, to determine whether trends in promotion were correlated with changes in the pharmaceutical pipeline, we examined the number of products and spending per product promoted.
Methods

Data
We used the IMS Health Integrated Promotional Services TM to obtain data on detailing, free samples dispensed to providers, and journal advertisements. We obtained data from SDI on spending for electronic promotion (e.g., Internet) targeting providers and for meetings and conferences. IMS Health detailing estimates are derived from a nationally representative audit of office-and hospital-based providers as well as pharmacy directors. Officebased detailing includes spending on service visits associated with sample distribution. Estimates of units of free samples dispensed to physicians are derived from an audit of office-based physician practices, while their retail value is calculated based on suggested retail prices. Journal advertising data is collected through a census of all medical journals. Using directory information from the American Medical Association, IMS also reports detailing expenditures by physician specialty. SDI spending is based on a monthly audit of approximately 4,000 office-based providers representing 19 specialties. Data are collected and projected by region and specialty to represent a universe of approximately 380,000 practicing providers. Finally, Kantar Media provided industry-wide and product-specific DTCA expenditures accounting for television, magazine, radio, outdoor, newspaper, and Internet promotion. These estimates are drawn from a sample of national media such as network TV and national newspapers as well as local media sampled at the Designated Media Area level.
We used IMS Health sales figures [7] , supplemented for certain therapies with data from the IMS Health National Sales Perspectives TM , in order to calculate promotion and marketing as a percentage of total sales. Estimates of the annual sales were calculated based on unit sales from both retail and non-retail channels and ex-manufacturer invoices (amount paid to wholesalers or manufacturers net of prompt payment discounts). We obtained data on the number of products on the market and, of these, the number promoted each year using IMS Health National Sales Perspectives TM and Integrated Promotional Services TM . We used a data set of drug launches [10] , supplemented for 2009 and 2010 with the number of new molecular entities approved by the Food and Drug Administration [20] , to determine the number of new molecular entities per year.
Biologic therapies were defined as those manufactured using biologic processes [10] , while the remainder of products were categorized as small molecules.
Analyses
We used descriptive statistics to characterize six aspects of promotion to providers: the retail value of free samples, officebased detailing, hospital-based detailing, journal advertising, epromotion and conferences and meetings. We quantified the absolute and relative magnitude of annual total promotional efforts towards providers. We also assessed the concentration of promotion for top-selling small molecules and biologic therapies.
We obtained a list of the top-selling U.S. and European biologics in 2010 [21] . We then identified additional biologics with high sales expenditures [22] and used the IMS Health National Sales Perspectives TM to rank these therapies. Sales and promotional expenditures were aggregated across all formulations of a brand, and for the few molecules available both as monotherapies and fixed-dose combinations, we excluded sales and promotional spending associated with combination therapies. Except where otherwise noted, data on sales and promotional spending were adjusted to 2010 dollars using the Consumer Price Index -All Urban [23] . 
Results
Trends in Overall and Provider Promotion
Drug Launches and Overall Number of Products Promoted
The number of new molecular entities launched ranged from 19 to 31 across the study period, with the greatest numbers of new molecular entities introduced between 2001 and 2003 (Table 1) . Declines in the number of products promoted paralleled declines in promotional spending. The average promotional spending per product actually increased from $9.0M (2001) to $12.0M (2006), then declined modestly to $11.2M (2010). All data were adjusted to 2010 dollars, utilizing the Consumer Price Index. Primary care providers include those trained in family practice, general practice, internal medicine, osteopathic medicine or pediatrics. Specialty providers were defined as all other provider types, including those trained in subspecialties of internal medicine such as cardiology or gastroenterology. ''-'' indicates years when data was not available. Table 2, 16 were small molecule therapies and the remaining nine were biologics.
Levels and intensities of provider and consumer-directed promotion were generally lower for biologics than small molecule therapies. The top 15 small molecule therapies had an average total promotional spending of $370 million in 2010 (8.8% of sales) compared to only $33 million for the top 15 biologics (1.4% of sales). Table 3 displays the 25 drugs most heavily promoted to consumers via DTCA. The drug most heavily promoted to consumers in 2010 was Lipitor with $272M devoted to DTCA alone followed by Cialis ($216M) and Cymbalta ($206M). DTCA was concentrated in a small number of products. Only two of the top 25 consumer-promoted products, etanercept (Enbrel) and golimumab (Simponi), were biologic therapies, whereas biologics accounted for 9 of the 25 top-selling products. Table 4 reports top US-selling biologics along with productspecific expenditures and promotional spending toward consumers and providers. In 2010, epoetin alfa (Epogen), infliximab (Remicade) and etanercept (Enbrel) led in biologic sales, each with $3.3B. Among top-selling biologic therapies, 2010 promotion was greatest for exenatide (Byetta) with 20% of its $571M in US sales dedicated to promotion, followed by insulin detemir (Levemir) with 12% and insulin glargine (Lantus) with 5% of its $3.0B in U.S. sales dedicated to promotion. Promotion for 17 of the other top-selling 25 biologics was less than 1% of sales.
Products Most Heavily Promoted to Consumers
Promotion of Biologics
Spending on promotion to providers varied widely across the biologics examined, ranging from only $83,000 (filgrastim [Neupogen]) to more than $100 million (insulin glargine [Lantus] and exenatide [Byetta] ). For the majority of therapies, office-based detailing accounted for the largest expenditures; however, among the minority of biologics that had any spending on free samples (e.g., Byetta, Lantus, Levemir), this was generally the dominant form of promotion. DTCA for biologics was limited to approximately two-thirds of the 25 therapies examined. Table 5 summarizes trends in detailing and contacts directed at primary care providers and specialists (excluding free samples). The proportion of office-based detailing directed at primary care providers declined modestly from 69% of contacts in 2002 to 63% in 2010. However, smaller decreases were evident in the share of office-based detailing spending targeting primary care physicians.
Promotion to Primary Care Physicians and Specialists
Discussion
After steady increases in pharmaceutical marketing and promotion to consumers and providers during the first half of the last decade, since 2004 pharmaceutical firms have decreased both the absolute value of spending as well as the share of sales devoted to promotion. These declines in promotional spending do not seem to primarily reflect waning consumer purchasing power, since promotion has been declining in the context of rising sales [7] . Spending on meetings and electronic promotion has increased, yet these channels still account for only a small fraction of provider promotion. Despite its growth in the first half of the decade, DTCA also represents a minority of promotion and is driven by television advertising. Top-selling biologic therapies had far lower promotional spending per product than did the top small molecule therapies, with substantially less spent on free samples.
Declines in promotion as a percentage of sales since 2005 may result in part from the ''graying'' of the market [1] . Whereas sales for new drugs accounted for 34% of total sales in 1999 they comprised only 19% of total sales in 2007 [8] . Reductions in new molecular entity approvals are apparent when considering the 1990s. On average, 22 new molecular entities were introduced annually in the 1980s, 31 in the 1990s, and 24 in the 2000s [24] .
Declining promotion may also reflect the increasing biologics share of the market [10] . Biologics often have unique routes of delivery and storage and can be very costly compared to small molecules, with costs for one cancer drug, Avastin, exceeding $100,000 per year [25] . Given that use of new biologics is concentrated among a smaller number of patients with relatively rare conditions treated primarily by specialists, we would expect promotion to providers and consumers to also be highly targeted.
Despite anecdotal reports [26, 27] and calls from stakeholders [27] [28] [29] , we did not find evidence of substantial changes in the proportion of provider-targeted promotion accounted for by office-based detailing. In addition, we saw no substantial shifts in the proportion of expenditures targeting primary care providers.
DTCA remains highly concentrated among a small number of products and continues to account for a minority of promotional spending [30] . Declines in DTCA may accelerate as biologics make up a greater share of new therapies. Although relative increases in DTCA through media such as the Internet and social networking have occurred, these expenditures remain a small fraction of overall consumer-targeted promotion.
Our study has several limitations. First, our analyses were not designed to examine promotional content nor the causal effect of promotional expenditures [31] [32] [33] . Second, some biologics have unique distribution channels and thus our data capture may be incomplete. The difficulty in measuring the extended units for infused and injected therapies also prohibits us from estimating the ratio of promotion to units of utilization. Third, while there are a variety of methods of estimating promotion costs [34] , we have used a conventional commercial definition and have considered only expenditures that are clearly directed at marketing rather than attempting to approximate unmonitored promotion and the R&D proportion that is promotional. Our estimates are similar to those of Donohue et al [1] although here we include estimates of expenditures for conferences and meetings as well as Epromotion to providers. As with prior investigations [1] , our estimations of promotion devoted to free samples are based on their approximate retail value and thus may overstate manufacturers' costs. Finally, to the extent medical care prices have increased more rapidly than non-medical care prices, our use of the Consumer Price IndexAll Urban may underestimate the magnitude of the reduction in inflation-adjusted drug spending since 2006.
Manufacturers of branded pharmaceuticals continue to expend considerable sums on promotion to consumers and providers. However, in the context of marketplace changes, firms are decreasing spending but changing little about how expenditures are allocated across types of promotion. An increasing role for biologics to the market may cause more substantial shifts in future promotional patterns.
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